DDInter712 DDInter1435
Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</sub> receptor antagonists, famotidine displays high selectivity towards this receptor; in a study consisting of healthy volunteers and patients with acid hypersecretory disease, famotidine was about 20 to 50 times more potent at inhibiting gastric acid secretion than [cimetidine] and eight times more potent than [ranitidine] on a weight basis. Famotidine is used in various over-the-counter and off-label uses. While oral formulations of famotidine are more commonly used, the intravenous solution of the drug is available for use in hospital settings.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Famotidine {u} (Compound) binds {v} (Gene) SLC47A1
Famotidine {u} (Compound) upregulates {v} (Gene) IFNAR1
Famotidine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H2 Receptor Antagonists
Famotidine {u} (Compound) downregulates {v} (Gene) PCNA
Famotidine {u} (Compound) causes {v} (Side Effect) Jaundice
Famotidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Raltegravir
Famotidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ketorolac
Famotidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Famotidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Fluoxetine
Famotidine {u} may lead to a major life threatening interaction when taken with {v} Dasatinib
Famotidine (Compound) binds SLC47A1 (Gene)
Famotidine (Compound) upregulates IFNAR1 (Gene)
Famotidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class)
Famotidine (Compound) downregulates PCNA (Gene)
Famotidine (Compound) causes Jaundice (Side Effect)
Famotidine may cause a minor interaction that can limit clinical effects when taken with Raltegravir
Famotidine may cause a minor interaction that can limit clinical effects when taken with Ketorolac
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine
Famotidine may lead to a major life threatening interaction when taken with Dasatinib